Cryoport Q4 Revenue $45.45M Exceeds Expectations
Reports Q4 revenue $45.45M, consensus $42.92M. Jerrell Shelton, CEO of Cryoport, commented, "2025 was a year of strong progress for Cryoport. We delivered full-year revenue of $176.2M, exceeding the high end of our previous guidance and reflecting continued momentum across our core markets. We achieved double-digit revenue growth driven by expanding cell and gene therapy activity, with revenue from the support of commercial CGTs increasing 29% year-over-year to a record $33.4M for FY25. Revenue from the support of clinical trials also remained solid, growing 14% to $47.1M for FY 2025. At year-end, we supported a record 760 global clinical trials, representing approximately 70% of CGT trials. We believe our leadership position across both clinical and commercial programs, and the breadth of the development pipeline we support, provide a substantial foundation for sustained long-term growth."
